Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

CHICAGO -- For people with heart failure (HF), the long-presumed benefits of fluid restriction did not pan out in the ...

“Right now, only 20% of patients with EGFR-positive NSCLC survive beyond five years,” explained Joshua Bauml, vice president, ...

Fifty-six percent of patients treated with RYBREVANT and LAZCLUZE were alive at three and a half years compared to 44 percent of patients ... patients with first-line EGFR-mutated NSCLC.

Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.

Black Americans face four times higher risk of kidney disease, with thousands undiagnosed due to healthcare gaps. Experts ...

The Phase III trial, which enrolled 1,074 patients, pitted the combination of Rybrevant and Lazcluze against AstraZeneca’s ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

As heart failure patients, the TAVI population studied already is recommended to be treated with an SGLT2 inhibitor, noted ...